Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Irene MedinaCecilia CarpioIsabel Ruiz-CampsAdaia Albasanz-PuigOriana Lopez-GodinoJuliana EsperalbaFrancisco BeasMario Sanchez-SalinasGloria IacoboniPere BarbaPublished in: Immunotherapy (2023)
Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most frequent complications after CAR T-cell therapy. Most of these infections are bacterial, although viral infections can also occur in this setting. Adenovirus-induced hemorrhagic cystitis is a rare infectious complication and is usually observed after bone marrow or solid organ transplantation. Herein we report a case of adenovirus-induced hemorrhagic cystitis in a patient experiencing urinary symptoms within the first month after CAR T-cell infusion. Based on our experience and a literature review, we discuss the diagnostic approach and potential treatment options for this infrequent infection after CAR T-cell therapy.
Keyphrases
- cell therapy
- diffuse large b cell lymphoma
- mesenchymal stem cells
- high glucose
- bone marrow
- stem cells
- case report
- diabetic rats
- epstein barr virus
- drug induced
- sars cov
- induced apoptosis
- acute lymphoblastic leukemia
- acute myeloid leukemia
- low dose
- physical activity
- depressive symptoms
- drug delivery
- climate change
- cell death
- hodgkin lymphoma
- endoplasmic reticulum stress
- replacement therapy